NASDAQ:IMVT

Immunovant Stock Forecast, Price & News

$48.67

-0.71 (-1.44 %)

(As of 11/24/2020 12:00 AM ET)

Add

Compare

Today's Range

$48.36

Now: $48.67▼

$49.67

50-Day Range

$36.75

MA: $44.97▼

$52.71

52-Week Range

$8.34

Now: $48.67▼

$53.75

Volume189,228 shs

Average Volume352,605 shs

Market Capitalization$4.76 billion

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Beat the Market (BTM) Rank^™

2.5 Analyst's Opinion

Consensus Rating
Immunovant has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 16 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $47.75, Immunovant has a forecasted downside of 1.9% from its current price of $48.67.
Amount of Analyst Coverage
Immunovant has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.7 Community Rank

Outperform Votes
Immunovant has received 42 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Immunovant has received 15 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Immunovant has received 73.68% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Immunovant and other stocks. Vote “Outperform” if you believe IMVT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IMVT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Immunovant does not currently pay a dividend.
Dividend Growth
Immunovant does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Immunovant insiders have bought more of their company's stock than they have sold. Specifically, they have bought $12,730,850.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 0.24% of the stock of Immunovant is held by insiders.
Percentage Held by Institutions
Only 33.94% of the stock of Immunovant is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Immunovant are expected to decrease in the coming year, from ($1.43) to ($1.67) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Immunovant is -31.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Immunovant is -31.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Overall Beat the Market Rank^™

1.57 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:IMVT

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.immunovant.com

Phone917-580-3099

Employees42

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares97,891,000

Market Cap$4.76 billion

Next Earnings Date2/12/2021 (Estimated)

OptionableNot Optionable

$48.67

-0.71 (-1.44 %)

(As of 11/24/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive IMVT News and Ratings via Email

Sign-up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter.

Immunovant (NASDAQ:IMVT) Frequently Asked Questions

How has Immunovant's stock price been impacted by COVID-19?

Immunovant's stock was trading at $14.14 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IMVT stock has increased by 244.2% and is now trading at $48.67.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Immunovant?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last year. There are currently 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Immunovant.

What stocks does MarketBeat like better than Immunovant?

Wall Street analysts have given Immunovant a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Immunovant wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Immunovant's next earnings date?

Immunovant is scheduled to release its next quarterly earnings announcement on Friday, February 12th 2021.
View our earnings forecast for Immunovant.

How were Immunovant's earnings last quarter?

Immunovant, Inc. (NASDAQ:IMVT) released its quarterly earnings data on Thursday, November, 12th. The company reported ($0.25) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.31) by $0.06.
View Immunovant's earnings history.

What price target have analysts set for IMVT?

16 Wall Street analysts have issued 1-year price targets for Immunovant's stock. Their forecasts range from $27.00 to $64.00. On average, they anticipate Immunovant's stock price to reach $47.75 in the next year. This suggests that the stock has a possible downside of 1.9%.
View analysts' price targets for Immunovant.

Who are some of Immunovant's key competitors?

Some companies that are related to Immunovant include Novozymes A/S (NVZMY), argenx (ARGX), Bio-Techne (TECH), QIAGEN (QGEN), Repligen (RGEN), Neurocrine Biosciences (NBIX), CRISPR Therapeutics (CRSP), Denali Therapeutics (DNLI), Acceleron Pharma (XLRN), Adaptive Biotechnologies (ADPT), Novavax (NVAX), Halozyme Therapeutics (HALO), Kodiak Sciences (KOD), Iovance Biotherapeutics (IOVA) and Relay Therapeutics (RLAY).
View all competitors.

What other stocks do shareholders of Immunovant own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunovant investors own include salesforce.com (CRM), NVIDIA (NVDA), Advanced Micro Devices (AMD), The Walt Disney (DIS), Fulcrum Therapeutics (FULC), Myovant Sciences (MYOV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), JD.com (JD) and Johnson & Johnson (JNJ).

Who are Immunovant's key executives?

Immunovant's management team includes the following people:

Dr. Peter Salzmann M.B.A., M.D., CEO & Director (Age 53, Pay $1.09M)
Ms. Pamela Yanchik Connealy M.B.A., Chief Financial Officer (Age 58, Pay $544.84k)
Dr. Julia G. Butchko Ph.D., Chief Devel. & Technology Officer (Age 49)
Dr. Michael J. Elliott MBBS, Ph.D., Chief Scientific Officer (Age 61)
Dr. Alan Jacobs M.D., VP & Head of Neurology Devel.
Dr. Ann M. Daus, VP & Head of Global Quality

What is Immunovant's stock symbol?

Immunovant trades on the NASDAQ under the ticker symbol "IMVT."

Who are Immunovant's major shareholders?

Immunovant's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.02%), Polar Capital LLP (1.79%), Polar Capital LLP (1.79%), Point72 Asset Management L.P. (1.72%), Perceptive Advisors LLC (1.59%) and State Street Corp (1.31%). Company insiders that own Immunovant stock include Julia G Butchko and Sciences Ltd Roivant.
View institutional ownership trends for Immunovant.

Which institutional investors are selling Immunovant stock?

IMVT stock was sold by a variety of institutional investors in the last quarter, including Camber Capital Management LP, Polar Capital LLP, Polar Capital LLP, Jane Street Group LLC, Quantitative Systematic Strategies LLC, SG Americas Securities LLC, Morgan Stanley, and Signaturefd LLC.
View insider buying and selling activity for Immunovant.

Which institutional investors are buying Immunovant stock?

IMVT stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., BlackRock Inc., State Street Corp, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Perceptive Advisors LLC, Vivo Capital LLC, and Peregrine Capital Management LLC. Company insiders that have bought Immunovant stock in the last two years include Julia G Butchko, and Sciences Ltd Roivant.
View insider buying and selling activity for Immunovant.

How do I buy shares of Immunovant?

Shares of IMVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Immunovant's stock price today?

One share of IMVT stock can currently be purchased for approximately $48.67.

How big of a company is Immunovant?

Immunovant has a market capitalization of $4.76 billion. Immunovant employs 42 workers across the globe.

What is Immunovant's official website?

The official website for Immunovant is www.immunovant.com.

How can I contact Immunovant?

Immunovant's mailing address is 320 WEST 37TH STREET, NEW YORK NY, 10018. The company can be reached via phone at 917-580-3099.

This page was last updated on 11/25/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings